CTI BIOPHARMA CORP. STOCK OPTION AGREEMENTStock Option Agreement • October 24th, 2016 • Cti Biopharma Corp • Pharmaceutical preparations • Washington
THIS STOCK OPTION AGREEMENT (the “Option Agreement”) is dated as of October 20, 2016 (the “Grant Date”) by and between CTI BioPharma Corp., a Washington corporation (the “Corporation”), and Richard L. Love (the “Participant”). Capitalized terms used herein and not otherwise defined shall have the meaning assigned to such terms in the Plan.
ASSET RETURN AND TERMINATION AGREEMENTAsset Return and Termination Agreement • October 24th, 2016 • Cti Biopharma Corp • Pharmaceutical preparations • New York
This Asset Return and Termination Agreement (this “Agreement”), effective as of October 21, 2016 (the “Effective Date”), is made by and between Baxalta Incorporated, a Delaware corporation (“BI”), Baxalta US Inc., a Delaware corporation (“BUSI”), Baxalta GmbH, a Swiss corporation (“BGMBH” and, together with BI and BUSI, collectively, “Baxalta”), and CTI BioPharma Corp. (f/k/a Cell Therapeutics, Inc.), a corporation organized and existing under the laws of the State of Washington (“CTI”). Baxalta and CTI are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CTI BIOPHARMA CORP.Compensation Agreement • October 24th, 2016 • Cti Biopharma Corp • Pharmaceutical preparations • Washington
This letter agreement (this “agreement”) confirms the terms of your employment with CTI BioPharma Corp. (the “Company”) as interim Chief Executive Officer (“Interim CEO”).
October 19, 2016 Mr. Matthew Plunkett CT1 BioPharma, Inc. 3103 Western Avenue Suite #600 Seattle, WA 98121 Re: Side Letter #2 on Term Sheet Timing Issues Dear Mr. Plunkett:Cti Biopharma Corp • October 24th, 2016 • Pharmaceutical preparations
Pursuant to Section 16.7 of the Development, Commercialization and License Agreement, dated November 14, 2013, as previously amended by that certain letter agreement re Side Letter on Term Sheet Timing Issues, dated September 19, 2016, between CTI BioPharma Corp. and Baxalta US Inc., as well as all other previous amendments (the “DCLA”), this letter, for good and valuable consideration, further amends that agreement.
